Validation of a Multiplex mRNA- and gDNA-Based Droplet Digital PCR Assay in Acute Myeloid Leukemia Patients with an <i>NPM1</i> Mutation
We developed a robust and extremely flexible mRNA- and gDNA-based multiplex droplet digital PCR NPM1 assay. Because the AML tumor load is better reflected by mutant NPM1 VAF than expression level, we recommend using the gDNA-based mutant NPM1 MRD assay with a VAF detection limit of 0.01%. For MRD signals below 0.01%, our more sensitive mRNA-based method can be used, although further research has to prove its clinical impact.
Authors
- Arjan Simpelaar
- Jan Jacob Schuringa (ORCID: https://orcid.org/0000-0001-8452-8555)
- Linde M. Morsink (ORCID: https://orcid.org/0000-0001-5408-5298)
- Isidor Minović (ORCID: https://orcid.org/0000-0002-5439-3781)
- Carolien M. Woolthuis (ORCID: https://orcid.org/0000-0002-6631-645X)
- Lucy B Hesp
- Gerwin A. Huls (ORCID: https://orcid.org/0000-0002-7120-898X)
- André B. Mulder
- Albertus T.J. Wierenga
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Clinical Chemistry
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1093/clinchem/hvaf142
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00